Document is current
Any future updates will be listed below
-
Authors
Kamal, Omar
Roudenko, Alexandra
Diab, Mahmoud
Shenoy-Bhangle, Anuradha
Lee, James
Sirlin, Claude B.
Fung, Alice
Elsayes, Khaled M.
- License Information
-
More Information
Article History
Received: 22 October 2024
Revised: 14 December 2024
Accepted: 16 December 2024
First Online: 24 December 2024
Declarations
:
: Dr. Sirlin reports payment to institution for research grants from ACR, Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens, V Foundation; payment to institution for lab service agreements with OrsoBio, Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; payment to institution for institutional consulting for BMS, Exact Sciences, IBM-Watson, Pfizer; Personal consulting for Altimmune, Ascelia Pharma, Blade, Boehringer, Epigenomics, Guerbet, Livivos, and Novo Nordisk; payment to self for royalties and/or honoraria from Medscape, Wolters Kluwer, and HealthProMatch; ownership of stock options in Livivos; unpaid advisory board position in Quantix Bio; executive position for Livivos (Chief Medical Officer, unsalaried position with stock options and stock) through June 28, 2023; Principal Scientific Advisor to Livivos (unsalaried position with stock options and stock) since June 28, 2023; payment to self for serving as a speaker for HealthProMatch; support for attending meetings and/or travel from Fundacion Santa Fe, Congreso Argentino de Diagnóstico por Imágenes, Stanford, Jornada Paulista de Radiologia, Ascelia Pharma, RSNA, Sociedad Radiológica de Puerto Rico, Hospital Español Auxilio Mutuo de Puerto Rico, Paris MASH, and Liver Forum; member (no payment) of Data Safety Monitoring board for National Cancer Institute funded Early Detection Research Network; equipment loans to institution from Butterfly, GE, Siemens, and Mayo; provision of contrast material to institution from Bayer.
